VRTX Stock Analysis: Buy, Sell, or Hold?
VRTX - Vertex Pharmaceuticals Inc
$528.04
30.03 (6.03%)
▲
5d:
+9.97%
30d:
+24.22%
90d:
+18.06%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 03, 2026
30d
Smart Money Distribution
None View Scanner →
Strength: 6.1/10
Get Alerted When VRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: VRTX is 9.2% above its trading range ($483.70). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: VRTX is 9.2% above its trading range ($483.70). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$675.51
Based on 8.1% avg growth
INTRINSIC VALUE TODAY
$419.44
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VRTX is currently trading at $528.04, which is considered extended relative to its 30-day fair value range of $433.49 to $483.70. From a valuation perspective, the stock is trading at a premium (Forward PE: 24.6) compared to its historical average (21.4). At these levels, the market is pricing in 4.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VRTX is in a strong downtrend. The price is approaching resistance at $529.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: VRTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VRTX is in a strong downtrend. The price is approaching resistance at $529.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: VRTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$433.49 -
$483.70
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
VRTX is technically overbought (RSI 81). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+9.2% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.0%)
- NEUTRAL: Near Wall St target ($548.69)
- NEUTRAL: Market pricing in 4.7% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$433.49 -
$483.70
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$450.39
Resistance Level
$529.14
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.59
Wall Street Target
$548.69
(+3.9%)
Revenue Growth (YoY)
7.8%
Earnings Growth (YoY)
61.4%
Profit Margin
35.5%
Valuation Premium vs History
+4.7% premium
PE vs Historical
24.6 vs 21.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.7%
(market-implied from PE analysis)
1-Year Target
$552.86
(+5%)
2-Year Target
$578.84
(+10%)
3-Year Target
$606.05
(+15%)
3-Yr Target (if PE normalizes)
(PE: 25→21)
PE COMPRESSION
$527.37
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.6, Growth: 12.1%)
$744.77
(+41%)
Base:
(SPY PE: 21.8, Growth: 12.1%)
$659.59
(+25%)
Bear:
(PE: 18.5, Growth: 12.1%)
$560.65
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 29.59 | Current EPS (TTM): $16.83
Bull Case
$698.89
(+32%)
Analyst growth 27.6%, PE expands to 32.6
Base Case
$635.35
(+20%)
Market implied 27.6%, PE stable at 29.6
Bear Case
$338.65
(-36%)
Severe decline -20.0%, PE contracts to 25.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 6:08 PM ET
Data refreshes hourly during market hours. Next update: 7:08 PM
Data refreshes hourly during market hours. Next update: 7:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Joy Liu
SELL
978 shares
2026-04-01
Carmen Bozic
SELL
2329 shares
2026-03-13
Amit Sachdev
SELL
1846 shares
2026-02-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
Advanced VRTX Option Strategies
Professional options setups generated by AI based on today's VRTX price and gamma walls.
